Trials that use: Multiplicity adjustment
New to this method? Read the tutorial →
20,317 results
- Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors: Complete Statistical AnalysisIndependent statistical analysis of Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors: primary endpoint results, effect estimate with confidence…
- Phase IIIndependent statistical analysis of Electrical Stimulation for Critically Ill Post-Covid-19 Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05198466).
- Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM): Complete Statistical AnalysisIndependent statistical analysis of Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03023722).
- Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors: Complete Statistical AnalysisIndependent statistical analysis of Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL): Complete Statistical AnalysisIndependent statistical analysis of Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02391116).
- Phase II Dasatinib Study in Advanced Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Dasatinib Study in Advanced Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00546104).
- Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria: Complete Statistical AnalysisIndependent statistical analysis of Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis: primary endpoint results, effect estimate with…
- Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS): Complete Statistical AnalysisIndependent statistical analysis of Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01842646).
- Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG): Complete Statistical AnalysisIndependent statistical analysis of Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS): Complete Statistical AnalysisIndependent statistical analysis of Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01822691).
- Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis: Complete Statistical AnalysisIndependent statistical analysis of Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02024555).
- Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC: Complete Statistical AnalysisIndependent statistical analysis of Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00176605).
- Phase II Neoadjuvant in Inflammatory Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Neoadjuvant in Inflammatory Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00756470).
- Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML): Complete Statistical AnalysisIndependent statistical analysis of Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00379197).
- Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase II Pharmacokinetics Study of CAM2038: Complete Statistical AnalysisIndependent statistical analysis of Phase II Pharmacokinetics Study of CAM2038: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02710526).
- Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer: primary endpoint results, effect estimate…
- Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab: Complete Statistical AnalysisIndependent statistical analysis of Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Study of Alternating Sunitinib and Temsirolimus: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Alternating Sunitinib and Temsirolimus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01517243).
- Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML): Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Phase II Study of Doxorubicin and Avastin® in Sarcoma.: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Doxorubicin and Avastin® in Sarcoma.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00755261).
- Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy: primary endpoint results,…
- Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size…
- Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer’s Disease: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00299988).
- Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck: primary endpoint results, effect estimate with confidence interval,…
- Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes: primary endpoint results, effect estimate with confidence interval,…
- Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L): Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol…
- Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00434109).
- Phase II Study of TAK228 in Relapsed Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of TAK228 in Relapsed Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02727777).